Verition Fund Management’s Iterum Therapeutics ITRM Stock Holding History

Verition Fund Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,500	Closed	-$23K	–	3135
2022 Q2	$23K	Hold	7,500	–	–	﹤0.01%	2208
2022 Q1	$40K	Hold	7,500	–	–	﹤0.01%	2514
2021 Q4	$44K	Hold	7,500	–	–	﹤0.01%	2427
2021 Q3	$63K	Hold	7,500	–	–	﹤0.01%	1757
2021 Q2	$260K	Hold	7,500	–	–	﹤0.01%	1421
2021 Q1	$159K	Buy	+7,500	New	+$179K	﹤0.01%	1381

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Verition Fund Management's ITRM Position: Q3 2022 in Review

Verition Fund Management sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 7,500 shares — an estimated $23K sold.

Verition Fund Management first reported a position in ITRM in Q1 2021 and held it in 6 quarters. The position peaked at $260K in Q2 2021. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

Verition Fund Management reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
Verition Fund Management sold 7,500 Iterum Therapeutics shares in Q3 2022, an estimated $23K.
Verition Fund Management first reported a position in Iterum Therapeutics in Q1 2021 and held it in 6 quarters.
Verition Fund Management's Iterum Therapeutics position peaked at $260K in Q2 2021.
25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on Verition Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.